LivingGLP1
Study S001853

A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric Restriction

ClinicalTrials.gov record

Registration

Registration
NCT02616003
Study type
INTERVENTIONAL
Phase
PHASE4
Masking
NONE
Status
COMPLETED
Enrollment
50
Start
2014-04
Primary completion
2018-01
Lead sponsor
Sana Klinikum Offenbach
Conditions
Morbid Obesity; Bariatric Surgery Candidate
Interventions
DRUG:Liraglutide; OTHER:Aminosteril hepa 8%; DIETARY_SUPPLEMENT:Caloric diet with 1000 kcal
Results posted
FALSE

Registered primary outcomes

  • Operability [21 days]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0020458Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity - A proof of concept study.
Stier C, Clinical nutrition ESPEN
2022Nonrandomized studyPMID 35871930DOIcites ClinicalTrials.gov:NCT02616003; registry reference DERIVED:35871930
R0022927A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, The New England journal of medicine
2015Randomized trialPMID 26132939DOIregistry reference RESULT:26132939
R0019732Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.
Baggio LL, The Journal of clinical investigation
2014CommentaryPMID 25202976DOIregistry reference RESULT:25202976